The acquisition
of the mass spectra was achieved using an
Autoflex III MALDI-time-of-flight(TOF) mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped
with a Smartbeam Nd:YAG laser (355 nm). The MALDI-MS method was optimized
for the detection of the three compounds by spotting freshly prepared
standards on a ground steel MALDI target plate and on an untreated
brain tissue section. External calibration was performed using CHCA
matrix ions and a
Peptide Calibration Standard Kit II (Bruker Daltonics).
Three batches of brain tissue sections were analyzed for each drug.
All experiments were carried out in the full-scan reflectron positive
mode within the mass range of
m/
z 100–550. The optimum laser power was kept at 65% for all
the compounds. Each pixel was collected with 500 shots per spectrum
in 10 random walk shot steps at a digitization rate of 0.5 GS s
–1 and a spatial resolution of 100 μm. The LIFT
MS/MS experiments were performed in brain tissues to further confirm
each analyte, and the data is reported in
Table S6.
Ntshangase S., Mdanda S., Singh S.D., Naicker T., Kruger H.G., Baijnath S, & Govender T. (2019). Mass Spectrometry Imaging Demonstrates the Regional Brain Distribution Patterns of Three First-Line Antiretroviral Drugs. ACS Omega, 4(25), 21169-21177.